Subscribe To
HOTH / Why Hoth Therapeutics Shares Are Rising
HOTH News
By InvestorPlace
June 6, 2023
Why Is Hoth Therapeutics (HOTH) Stock Up 83% Today?
Hoth Therapeutics (NASDAQ: HOTH ) stock is rocketing higher on Tuesday thanks to the company announcing positive results from a preclinical trial. Acc more_horizontal
By Benzinga
December 30, 2022
Why Hoth Therapeutics Shares Are Nosediving - Hoth Therapeutics (NASDAQ:HOTH)
Hoth Therapeutics Inc HOTH shares are trading lower by 21.22% to $8.44 Friday morning after the company announced a $10 million private placement pric more_horizontal
By Benzinga
July 12, 2022
Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program
Hoth Therapeutics Inc (NASDAQ: HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's dis more_horizontal
By Benzinga
July 12, 2022
Why Hoth Therapeutics Shares Are Skyrocketing Today
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic sh more_horizontal
By Benzinga
April 19, 2022
Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury
Hoth Therapeutics Inc (NASDAQ: HOTH) has added a new asset, HT-TBI, as a novel, point-of-care therapy to treat secondary brain injury resulting from more_horizontal
By InvestorPlace
April 11, 2022
Why Is Hoth Therapeutics (HOTH) Stock Skyrocketing 110% Today?
Hoth Therapeutics (HOTH) stock is rising higher on Monday after the biopharmaceutical company provided an update on HT-KIT. The post Why Is Hoth Thera more_horizontal
By Benzinga
April 11, 2022
Hoth Therapeutics' Novel Cancer Drug Prevented Cell Growth, Induced Cell Death Over 72 hours
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are surging after announcing development updates for its novel cancer therapeutic, HT-KIT. Through a sp more_horizontal
By Benzinga
April 11, 2022
Why Hoth Therapeutics Shares Are Rising
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 125.5% at $1.38 after the company said its mRNA frame-shifting therapeutic proved ef more_horizontal